Inyx's new marketing subsidiary Exaeris begins operations

By E. Janene Geiss

Philadelphia, Jan. 4 - Inyx, Inc., a specialty pharmaceutical company with a focus on niche drug delivery technologies and products, announced Wednesday that its new, wholly owned sales and marketing subsidiary, Exaeris Inc., has started operations.

"Exaeris is focusing on the direction and execution of commercial activities independent of Inyx's client manufacturing operations," Jack Kachkar, chairman and chief executive officer of Inyx, said in the release.

"Through Exaeris, we will build the necessary commercial resources to drive additional revenues and benefits to Inyx and our industry partners," Kachkar added.

Stephen Beckman, vice president for sales & marketing and commercial development of Inyx, has been appointed to the additional position of president of Exaeris, the release said.

Beckman has more than 15 years of sales and marketing experience in the pharmaceutical industry, including having served in executive positions with Altana Pharma AG and SmithKline Beecham, officials said.

"Exaeris can capitalize on Inyx's niche drug delivery technologies, proprietary development platforms and strategic global relationships to create more opportunities for business collaborations and to commercialize customer products," Beckman said in the release.

"The establishment of Exaeris will now allow Inyx to operate as a vertically integrated specialty pharmaceutical organization with commercial and marketing resources as well as development and manufacturing operations," he added.

Exaeris is based in Exton, Pa., which provides the opportunity to participate in progressive state programs that support emerging pharmaceutical and biotechnology organizations, as well as have access to a significant base of pharmaceutical talent and developmental initiatives, officials said.

On Sept. 8 King Pharmaceuticals Inc. and Inyx announced a 10-year strategic alliance, which includes co-marketing collaboration on King's Intal (cromolyn sodium) and Tilade (nedocromil sodium) respiratory products in the United States and Canada.

Exaeris is initially directing the sales efforts to relaunch Intal in specialty markets - including to allergists, pulmonologists and pediatricians - starting this month, officials said.

Exaeris said it will expand the sales force in the second quarter of 2006, extending coverage in the specialty markets and also incremental reach to the top prescribing primary care physician markets.

"The prevalence and incidence of asthma and other respiratory conditions continues to rise. Exaeris is focused on supporting physicians and patients with valued products and services to support the improvement of therapeutic outcomes in respiratory treatments," Beckman said in the release.

"Intal and Tilade are the only non-steroidal anti-inflammatory asthma medications currently available, which makes them an appropriate substitute for corticosteroid respiratory drugs when concerned about the misuse and over use of corticosteroids being prescribed today to both children and adults," he said.

Inyx is a New York City specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.